This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Concert Pharmaceuticals Dividende
Dividende contrôle des critères 0/6
Informations clés
n/a
Rendement du dividende
n/a
Ratio de distribution
Rendement moyen de l'industrie | 1.9% |
Prochaine date de paiement du dividende | n/a |
Date ex-dividende | n/a |
Dividende par action | n/a |
Résultat par action | -US$2.04 |
Prévision de rendement du dividende | n/a |
Mises à jour récentes des dividendes
Pas de mise à jour
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Insufficient data to determine if CNCE's dividends per share have been stable in the past.
Dividende croissant: Insufficient data to determine if CNCE's dividend payments have been increasing.
Rendement des dividendes par rapport au marché
Concert Pharmaceuticals Rendement des dividendes par rapport au marché |
---|
Segment | Rendement du dividende |
---|---|
Entreprise (CNCE) | n/a |
25% du marché (US) | 1.4% |
25% du marché (US) | 4.4% |
Moyenne du secteur (Biotechs) | 1.9% |
Analyste prévisionnel (CNCE) (jusqu'à 3 ans) | n/a |
Dividende notable: Unable to evaluate CNCE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Dividende élevé: Unable to evaluate CNCE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Bénéfice distribué aux actionnaires
Couverture des revenus: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as CNCE has not reported any payouts.